MEK1 V221D mutation, which is localized within the arylamine binding pocket, emerged in a CRC patient following the treatment with MEKi binimetinib and anti-EGFR antibody panitumumab 74. This evidence concerns the gene MAP2K1 and colorectal carcinoma.